Primary biliary cholangitis (PBC) is a chronic autoimmune intrahepatic cholestatic liver disease characterized by progressive, non-suppurative, destructive cholangitis, potentially leading to fibrosis, cirrhosis, and liver failure. It predominantly affects middle-aged and elderly women, with highly variable progression rates: some patients remain stable long-term, while others rapidly develop portal hypertension and decompensation. Early risk factor identification and accurate risk stratification are essential for improving prognosis.
Large-scale, multi-dimensional (clinical-pathological-laboratory) studies on PBC progression risk factors in the Chinese population remain scarce. The associations of histological stage, autoantibody profiles, and biochemical response with prognosis require further clarification.
This retrospective observational study will enroll PBC patients with histologically confirmed diagnosis via liver biopsy at Beijing Ditan Hospital, Capital Medical University, from January 2015 to June 2026. We will systematically analyze clinical, laboratory, autoantibody, and pathological features. Univariate and multivariate logistic/Cox regression will be used to identify independent risk factors, aiming to establish a progression risk prediction model tailored to Chinese PBC patients. This model will support early identification of high-risk individuals and guide personalized treatment and follow-up strategies in clinical practice.
Inclusion Criteria:
Exclusion Criteria:
PBC patients who experienced disease progression during follow-up, defined as histological stage progression (≥1 stage by Ludwig system), decompensated cirrhosis events (ascites, variceal bleeding, or hepatic encephalopathy), liver transplantation, or liver-related death.
PBC patients who did not experience any of the above events during follow-up and remained alive without liver transplantation at the last follow-up visit.
Beijing, Beijing Municipality 100015, China
wuhm2000@sina.com8613693259096
PBC Long-term Outcomes Study
Retrospective Study About Primary Biliary Cholangitis During January 2001 to July 2016 at West China Hospital
Biochemical Response and Clinical Outcomes in Patients With PBC
A 5-year Longitudinal Observational Study of Patients With Primary Biliary Cholangitis
Detection Program for Patients With Primary Biliary Cholangitis Lost in the System
Performance of Scoring Systems in Chinese Patients With Primary Biliary Cholangitis (PBC) on Ursodeoxycholic Acid
Austrian PBC Registry
Identification of the Genetic Variants Responsible for Primary Biliary Cirrhosis (PBC)